oncteranl logo
  • About
    • Overview
    • Leadership
  • Pipeline
    • Overview
    • ONCT-808
    • ONCT-534
    • Zilovertamab
  • Science
    • Overview
    • Publications
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Financial Reports
    • Stock Information
    • Analyst Coverage
    • Corporate Governance
  • Patients
  • Careers
    • Current Opportunities
    • Vision, Mission and Impact
  • Contact

Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma (Yu et al., Oncotarget 2018)

BACK TO HOME

Contact

© 2016 - 2024 Oncternal Therapeutics. All rights reserved

logo
  • About
    • Overview
    • Leadership
  • Pipeline
    • Overview
    • ONCT-808
    • ONCT-534
    • Zilovertamab
  • Science
    • Overview
    • Publications
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Financial Reports
    • Stock Information
    • Analyst Coverage
    • Corporate Governance
  • Patients
  • Careers
    • Current Opportunities
    • Vision, Mission and Impact
  • Contact